Morgan Stanley Atreca, Inc. Transaction History

Morgan Stanley

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$0.13 - $0.38 $592 - $1,731	4,556 New	4,556 $0
Q4 2023 Feb 13, 2024	BUY	$0.13 - $0.38 $7 - $22	58 Added 1.29%	4,556 $0
Q3 2023 Nov 15, 2023	SELL	$0.26 - $1.12 $26,828 - $115,569	-103,187 Reduced 95.82%	4,498 $1,000
Q2 2023 Aug 14, 2023	BUY	$0.88 - $1.22 $217 - $301	247 Added 0.23%	107,685 $105,000
Q1 2023 May 15, 2023	SELL	$0.91 - $1.82 $2,086 - $4,173	-2,293 Reduced 2.09%	107,438 $122,000
Q4 2022 Feb 14, 2023	SELL	$0.78 - $1.68 $56,020 - $120,659	-71,821 Reduced 39.56%	109,731 $87,000
Q3 2022 Nov 14, 2022	SELL	$1.59 - $2.74 $188,147 - $324,229	-118,332 Reduced 39.46%	181,552 $285,000
Q2 2022 Oct 27, 2022	BUY	$1.56 - $3.25 $228,153 - $475,319	146,252 Added 95.2%	299,884 $536,000
Q2 2022 Aug 15, 2022	BUY	$1.56 - $3.25 $228,153 - $475,319	146,252 Added 95.2%	299,884 $536,000
Q1 2022 Oct 27, 2022	SELL	$1.61 - $5.2 $235,465 - $760,510	-146,252 Reduced 48.77%	153,632 $487,000
Q1 2022 May 13, 2022	SELL	$1.61 - $5.2 $130,640 - $421,943	-81,143 Reduced 34.56%	153,632 $487,000
Q4 2021 Feb 14, 2022	BUY	$2.87 - $6.29 $137,671 - $301,725	47,969 Added 25.68%	234,775 $711,000
Q3 2021 Nov 15, 2021	BUY	$4.91 - $9.07 $917,217 - $1.69 Million	186,806 New	186,806 $1.16 Million

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.